Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes

Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more...

Descripción completa

Detalles Bibliográficos
Autores principales: Skolnik, Neil, Del Prato, Stefano, Blonde, Lawrence, Galstyan, Gagik, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004501/
https://www.ncbi.nlm.nih.gov/pubmed/33620694
http://dx.doi.org/10.1007/s12325-020-01614-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004501/
https://www.ncbi.nlm.nih.gov/pubmed/33620694
http://dx.doi.org/10.1007/s12325-020-01614-5

Ejemplares similares